Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New findings explain how lysosomal defects trigger neuronal energy failure

23

Jan 2026

New findings explain how lysosomal defects trigger neuronal energy failure

Together with colleagues from Stanford University, USA, researchers at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) have, for the first time, created a comprehensive cell type-specific atlas of lysosomes in the brain, the cell organelles which are responsible for degradation and recycling processes.

Sedentary adulthood increases biological stress levels by middle age

23

Jan 2026

Sedentary adulthood increases biological stress levels by middle age

Prolonged insufficient physical activity in adulthood increases the body's stress burden, according to a large longitudinal study based on the Northern Finland Birth Cohort 1966. By contrast, engaging in physical activity in line with recommended guidelines appears to protect the body from harmful stress.

Ageing slows brain protein clearance and shifts synaptic waste to microglia

22

Jan 2026

Ageing slows brain protein clearance and shifts synaptic waste to microglia

Ageing slows neuronal protein degradation in mice, leading to widespread accumulation and aggregation of long-lived proteins, particularly at synapses. As neuronal clearance declines, microglia selectively accumulate synaptic proteins, suggesting a compensatory but potentially strained proteostasis pathway in the ageing brain.

Nearly half of adults now live with heart disease as obesity and diabetes surge

22

Jan 2026

Nearly half of adults now live with heart disease as obesity and diabetes surge

The 2026 American Heart Association Heart Disease and Stroke Statistics report shows that nearly half of adults are living with cardiovascular disease, with cardiometabolic risk factors projected to rise substantially by 2050. Despite progress in smoking reduction and cholesterol control, worsening obesity, diabetes, hypertension, sleep health, and persistent inequities threaten future cardiovascular health.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.